Clinical Trial Solutions
Invicro’s clinical capabilities span from early phase, first-in-human through late phase and post-approval studies. We focus on studies containing imaging and pathology-based endpoints requiring robust, independent assessments to ascertain drug efficacy.
Our imaging core lab and CAP/CLIA lab-based pathology services solutions support various therapeutic areas including oncology, immuno-oncology, neurology (CNS), cardiovascular, musculoskeletal and gastrointestinal. Our experience comes from years of successful execution of Phase II-IV studies across the development spectrum led by a leadership team with an average of 25 years of industry experience.
As a leading imaging and pathology services provider, we acquire, store, analyze, and report data needed to help biopharmaceutical partners make decisions about their drug development programs. Invicro supports a broad range of modalities to evaluate key clinical endpoints in clinical studies including:
- NM bone scan
- Core histology
- Multiplex Immunohistochemistry (IHC)
- Multiplex Immunofluorescence (IF)
- Quanticell™ High sensitivity Immunohistochemistry (IHC)
- RNAScope® ISH
- BaseScope™ ISH
- Additional Modalities Available
Thought Leadership Content